Ann: Successful Completion of Phase 1b Breast Cancer Trial, page-24

Highly probable scenario @ the other one
No Ann re ceasing to be a substantial holder as yet though
Licensing by pharma has been known to not only occur at phase 1 or 2 or 3 but some at pre-clinical levels also. Of course, as studies advance terms of material gain also do
As a long term intendee, would prefer negotiations, if any, to occur at a later stage, regardless of the exemplifying data to date
At times, things often seem on the surface as face value, yet, we know, that often their are (at least) two sides to a story
In reference then....
What the placement instos will leave, if what u say is true re exiting.., is funding and, for some, the opportunity to increase their stake at heavily discounted SP
So, a thank you should be expressed
Luck to all holders.